Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: A case series and review of the literature

Cutis

Volumn 81, Issue 2, 2008, Pages 179-183

  Keeling, Jon ^a,e   Cardona, Lina ^b   Benitez, Adolpho ^b   Epstein, Rachel ^c   Rendon, Marta ^d,e  

^a Wellington Regional Medical Center   (United States)

^b Skin Care Research Inc   (United States)

^c Sun Coast Hospital   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-HYDROXYANISOLE; ANISOLE DERIVATIVE; ANTIOXIDANT; KERATOLYTIC AGENT; MEQUINOL; RETINOIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MELANOSIS; MIDDLE AGED; SKIN DISEASE; SOLUTION AND SOLUBILITY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANISOLES; ANTIOXIDANTS; FACIAL DERMATOSES; HUMANS; KERATOLYTIC AGENTS; MALE; MELANOSIS; MIDDLE AGED; SOLUTIONS; TREATMENT OUTCOME; TRETINOIN;

EID: 41149086044     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Grimes PE. Melasma, etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
2. Vázquez M, Maldonado H, Benmamán C, et al. Melasma in men: a clinical and histologic study. Int J Dermatol. 1988;27:25-27.
3. Sialy R, Hassan I, Kaur I, et al. Melasma in men: a hormonal profile. J Dermatol. 2000;27:64-65.
4. Sarkar R, Jain RK, Puri P. Melasma in Indian males [letter]. Dermatol Surg. 2003;29:204.
5. Lonsdale-Eccles AA, Langtry JA. Melasma on the nape of the neck in a man. Acta Derm Venereol. 2005;85:181-182.
6. Balkrishnan R, McMichael AJ, Hu JY, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006;45:111-115.
7. Balkrishnan R, Kelly AP, McMichael A, et al. Improved quality of life with effective treatment of facial melasma: the pigment trial. J Drugs Dermatol. 2004;3:377-381.
8. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-577.
9. Bessou S, Pain C, Taieb A. Use of human skin reconstructs in the study of pigment modifiers. Arch Dermatol. 1997;133:331-336.
10. García Reverte JM, Bernabeu Esclapez A, Muñoz Ramos J, et al. Effects of various antineoplastic agents on an established human melanoma cell line (G-361). Histol Histopathol. 1995;10:79-84.
11. Koga S, Nakano M, Ito T, et al. Importance of iron in lipid peroxidation in the tyrosinase/4-hydroxyanisole system: possible mechanism of killing of malignant melanoma cells by 4-hydroxyanisole. Biochem Int. 1992;26:397-403.
12. Moridani MY. Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells. Cancer Lett. 2006;243:235-245.
13. Gilchrest BA. Retinoids and photodamage. Br J Dermatol. 1992;127(suppl 41):14-20.
14. Griffiths CE, Voorhees JJ. Topical retinoic acid for photo-aging: clinical response and underlying mechanisms. Skin Pharmacol. 1993;6(suppl 1):70-77.
15. Kasraee B, Handjani F, Aslani FS. Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection? Dermatology. 2003;206:289-291.
16. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol. 1998;25:587-596.
17. Eichner R. Epidermal effects of retinoids: in vitro studies. J Am Acad Dermatol. 1986;15(4, pt 2):789-797.
18. Fleischer AB Jr, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42:459-467.
19. Jarratt M. Mequinol 2%/tretinion 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004;74:319-322.
20. Ortonne JP, Camacho F, Wainwright N, et al. Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretioin 0.01% solution and sunscreen in solar lentigines. Cutis. 2004;74:261-264.
21. Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol. 2006;5:239-244.
22. Hexsel DM. A study on the use of mequinol/tretinoin to prevent the reappearance of solar lentigines in patients previously treated with chemical peels and cryotherapy. Cosmet Dermatol. 2004;17:269-272, 274.
23. Stough D, Dugan T. Synergism between cryotherapy and application of depigmenting topical solution in the treatment of solar lentigines. J Am Acad Dermatol. 2004;50(suppl):172.
24. Breathnach AS, Diala EB, Gallagher SM, et al. Ultrastructural observations on the effect of 4-hydroxyanisole on normal human melanocytes in tissue culture. J Invest Dermatol. 1981;77:292-296.
25. Solagé [package insert]. Barrier Therapeutics, Inc: Princeton, NJ; 2007.
26. Hadler RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48(suppl 6):S143-S148.
27. Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. US Census Bureau. Released February 1996. http://www.census.gov/prod/1/pop/p25-1130.pdf. Accessed January 8, 2008.